EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comTechnology like AI/ML is spearheading big pharma companies by accelerating drug discovery. CROs are also stepping into the game by offering AI/ML solutions to help emerge and establish biopharmaceutical companies. Another notable trend is the merging of CRO and CDMO activities to improve the inconsistencies in the early clinical phase trials. This merge is profoundly impacting pharmaceutical manufacturing, specifically vaccine manufacturing, both traditional adenoviral vectors and validating novel mRNA-based vaccines. In the wake of these trends, the global CRO services market is projected to reach $163.48 billion by 2029, growing at a CAGR of 12.1 percent. The growth is especially driven by R&D budgets from pharmaceutical, biotechnology, medical device companies, governments, and medical research entities.To put the spotlight on such key developments in the industry, Pharma Tech Outlook illustrates how pharma companies in the APAC region are leveraging leading-edge CROs to augment their services. This edition also features thought leadership articles from subject matter experts on ongoing trends, best practices, and recent innovations. Some of the exclusive insights are authored by Philippe Caby, CIO, Centrient Pharmaceuticals, Gil Carrasquinho, VP of Advisory Global Corporate Development Division at Santen, and Philippe Marc, Executive Director, Global Head of Integrated Data Science, Novartis. They shed light on enhancing biotech capabilities and solutions for various medical prospects in the healthcare industry.In this edition of Pharma Tech Outlook magazine, we also bring to you the story of some of the top CROs in the APAC region that are facilitating unparalleled workflow optimizations for pharma companies and enhancing drug accessibility for patients. In the list, LinkChem particularly stands out for its broad experience and state-of-the-art infrastructure by making a difference by consolidating and combining a CRO + CDMO business model; HiRO stands out for its ability to deliver accelerated commercialization pathways to global biotech and pharma by providing innovative end to end clinical trial solutions; and WuXi AppTec for giving a platform that transforms pharma outlook.Through the following pages, we aim to highlight the innovative trends and latest developments in the CRO segment. We would like to know your thoughts.Threading CRO and CDMO to Enhance Therapeutics and Care DeliveryTECH OUTLOOKCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.OCTOBER - 03 - 2022, Vol 08 - Issue 06 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanMichael WayneEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, TECH OUTLOOK
< Page 5 | Page 7 >